The Nano-BODYTM platform-based development of bispecific antibody Y332D not only blocks both TGF-β and VEGF signaling pathways, but also establishes a physical link between the anti-TGF-β and anti-VEGF termini due to its unique molecular structure, allowing for better aggregation at the tumor site and exerting synergistic effects. The gene discussed is VEGFA; the disease is neoplasm.